Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade

28 Apr 2024

Abstract excerpt

Antisense oligonucleotides (ASOs) are short oligodeoxynucleotides designed to bind to specific regions of target mRNA. ASOs can modulate pre-mRNA splicing, increase levels of functional proteins, and decrease levels of toxic proteins. ASOs are being developed for the treatment of motor neuron diseases (MNDs), including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and spinal and bulbar...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis Research
Share to Neurogenetic and Muscular Disorders Research
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38732027
DOI: 10.3390/ijms25094809

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and ShadePMID 38732027Read ↗

Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shadeSemantic proximity Read ↗

Therapeutic antisense oligonucleotides for movement disordersSemantic proximity Read ↗

Recent Progress of Antisense Oligonucleotide Therapy for Superoxide Dismutase 1-mutated Amyotrophic Lateral Sclerosis: Focus on TofersenSemantic proximity Read ↗

Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen.Semantic proximity Read ↗

Antisense Drugs Make Sense for Neurological DiseasesSemantic proximity Read ↗

Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseasesSemantic proximity Read ↗

Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscapeSemantic proximity Read ↗

The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular AtrophySemantic proximity Read ↗

Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s diseaseSemantic proximity Read ↗

Challenges and future perspective of antisense therapy for spinal muscular atrophy: A reviewSemantic proximity Read ↗

Oligonucleotide therapeutics in neurodegenerative diseasesSemantic proximity Read ↗

Nusinersen in the Treatment of Spinal Muscular Atrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.